Compare ONEW & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | MDWD |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.3M | 181.1M |
| IPO Year | 2019 | 2013 |
| Metric | ONEW | MDWD |
|---|---|---|
| Price | $13.39 | $14.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $16.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 95.7K | 80.3K |
| Earning Date | 04-30-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | N/A |
| Revenue This Year | $0.30 | $48.92 |
| Revenue Next Year | $3.14 | $35.04 |
| P/E Ratio | $4.45 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $8.12 | $13.54 |
| 52 Week High | $17.92 | $21.11 |
| Indicator | ONEW | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 71.85 | 49.24 |
| Support Level | $10.11 | $13.65 |
| Resistance Level | $17.35 | $15.18 |
| Average True Range (ATR) | 0.71 | 0.55 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 97.45 | 43.48 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.